Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase 2 | terminated | Nov 7, 2018 | Oncotherapeutics | Insufficient enrollment | Enrollment / accrual |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone…(ClaSPd) | Phase 2 | terminated | Apr 13, 2021 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | Phase 2 | terminated | Sep 20, 2018 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in…(LOTIS-6) | Phase 2 | terminated | Jan 7, 2021 | ADC Therapeutics S.A. | Administrative decision (not due to safety reason) | Safety / toxicity |
| NCT03318861 | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With… | Phase 1 | terminated | Oct 24, 2017 | Kite, A Gilead Company | The study was terminated due to lack of efficacy | Efficacy / futility |
| NCT04805203 | Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma(Covimmunomm) | N/A | terminated | Mar 18, 2021 | Intergroupe Francophone du Myelome | Recruitment delay due to difficulties to involve patient at Covid diagnosis in hematology… | COVID-19 / pandemic |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 1 | withdrawn | May 19, 2023 | Innovent Biologics (Suzhou) Co. Ltd. | Development strategy adjustment | Sponsor / business decision |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine… | Phase 1 / Phase 2 | terminated | Nov 7, 2016 | Philogen S.p.A. | Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with… | Other (stated, no rule matched) |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for… | Phase 1 / Phase 2 | terminated | Aug 9, 2010 | Sherif Farag, MB, BS | Lack of accrual | Enrollment / accrual |
| NCT02204982 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously…(DYNAMO + R) | Phase 3 | terminated | Jul 31, 2014 | SecuraBio | Sponsor is focusing on studies which can enable registration of duvelisib | Other (stated, no rule matched) |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With… | Phase 1 / Phase 2 | terminated | Mar 18, 2015 | SecuraBio | Sponsor is focusing on studies which can enable registration of duvelisib. | Other (stated, no rule matched) |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed… | Phase 2 | terminated | Dec 19, 2019 | Srinivas Devarakonda | Poor accrual | Enrollment / accrual |
| NCT04692155 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2…(CHOP U2) | Phase 1 / Phase 2 | terminated | Dec 31, 2020 | University of Alabama at Birmingham | FDA hold | Other (stated, no rule matched) |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating… | Phase 1 / Phase 2 | withdrawn | Oct 10, 2018 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or… | Phase 1 | withdrawn | Mar 21, 2019 | M.D. Anderson Cancer Center | Request by sponsor due to no enrollment of participants on study | Enrollment / accrual |
| NCT04142619 | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With… | Phase 1 | terminated | Oct 29, 2019 | Cellectis S.A. | The trial was discontinued due to sponsor's decision and not a consequence of any safety concern. | Safety / toxicity |
| NCT04171843 | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With… | Phase 1 | terminated | Nov 21, 2019 | Precision BioSciences, Inc. | Study was terminated due to lack of sufficient therapeutic effect | Other (stated, no rule matched) |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Nov 4, 2020 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05698888 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | Phase 1 | terminated | Jan 26, 2023 | Virtuoso BINco, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory… | Phase 1 / Phase 2 | terminated | Jun 28, 2017 | University of Nebraska | Phase I response to treatment was not as expected and the myeloma field in treatment has changed… | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT04258683 | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide,… | Phase 2 | withdrawn | Feb 6, 2020 | Canadian Myeloma Research Group | Study terminated due to changing treatment landscape | Other (stated, no rule matched) |
| NCT04231734 | Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma | N/A | withdrawn | Jan 18, 2020 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk… | Phase 2 | terminated | Sep 20, 2016 | Hackensack Meridian Health | FDA Hold Due to Updated Risks | Other (stated, no rule matched) |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | Phase 2 | terminated | Oct 8, 2019 | Andrew Yee, MD | Study closure initiated by industry funding sponsor for commercial reasons. | Funding |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | Early Phase 1 | withdrawn | Jul 19, 2018 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | withdrawn | Jun 26, 2023 | ModernaTX, Inc. | The Sponsor decided to discontinue development of mRNA-2736 for strategic business reasons. | Sponsor / business decision |
| NCT03229382 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular…(OPERA-PLRG10) | Phase 2 | terminated | Jul 25, 2017 | Polish Lymphoma Research Group | Very slow recruitment due to lack of relapse in the observed group of patients | Enrollment / accrual |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | Phase 3 | terminated | Aug 31, 2015 | Gilead Sciences | Gilead has made the decision to close the study due to enrollment challenges | Enrollment / accrual |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Vaccine manufacturing has been suspended | Drug supply |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Phase 1 | terminated | Dec 30, 2019 | AstraZeneca | Strategic change to clinical development plan | Sponsor / business decision |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve… | Phase 2 | terminated | Feb 4, 2019 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 3, 2021 | Exelixis | Due to Sponsor reasons. | Other (stated, no rule matched) |
| NCT05604417 | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Nov 3, 2022 | Jacob Soumerai, MD | Termination of Zandelisib clinical development globally | Other (stated, no rule matched) |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Phase 1 | withdrawn | Jul 6, 2023 | Fate Therapeutics | This study was withdrawn (Sponsor decision). | Sponsor / business decision |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Nov 8, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT02588456 | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In… | Phase 1 | terminated | Oct 27, 2015 | University of Pennsylvania | This study was terminated due to lack of efficacy | Efficacy / futility |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen… | Early Phase 1 | terminated | Dec 28, 2015 | University of Pennsylvania | Study is terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | Phase 2 | terminated | Jun 9, 2016 | University of Pennsylvania | Study was terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With… | Phase 2 | terminated | Dec 20, 2018 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in…(LIGHTHOUSE) | Phase 3 | terminated | Dec 2, 2020 | Oncopeptides AB | The sponsor decided to terminate the study due to financial issues following an FDA request for a… | Funding |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | Phase 3 | terminated | Aug 6, 2015 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT05152459 | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or… | Phase 1 / Phase 2 | withdrawn | Dec 9, 2021 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT02063113 | Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.(MYELOME-PA) | N/A | terminated | Feb 14, 2014 | Nantes University Hospital | inclusion difficulty | Other (stated, no rule matched) |
| NCT03850028 | Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution… | N/A | withdrawn | Feb 21, 2019 | University Medical Center Groningen | Closed prematurely because the accrual was not achieved | Enrollment / accrual |
| NCT01728259 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | Phase 1 | terminated | Nov 19, 2012 | Barbara Ann Karmanos Cancer Institute | FDA placed the study on a clinical hold, due to the concerns by the FDA and Health Canada, Celgene… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 25, 2023source: clinicaltrials